Click Here for 5% Off Your First Aladdin Purchase!

Maraviroc - 98%, high purity , C-C chemokine receptor type 5 antagonist, CAS No.376348-65-1, C-C chemokine receptor type 5 antagonist

  • Moligand™
  • ≥98%
Item Number
M125486
Grouped product items
SKUSizeAvailabilityPrice Qty
M125486-5mg
5mg
In stock
$58.90
M125486-25mg
25mg
In stock
$265.90
M125486-100mg
100mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$616.90

Potent and selective CCR5 antagonist with potent anti-HIV activity

View related series
CCR5 Antagonist

Basic Description

SynonymsMaraviroc|376348-65-1|Selzentry|Celsentri|UK-427857|UK-427,857|UK 427857|MD6P741W8A|CHEMBL256907|CHEMBL584744|MVC|CHEMBL1201187|DTXSID8048949|CHEBI:63608|4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octa
Specifications & Purity98%
Legal InformationSold for only research purposes
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionC-C chemokine receptor type 5 antagonist
Product Description

Maraviroc has been used as a C-C chemokine receptor type 5 (CCR5-specific) inhibitor in murine monocyte/macrophage cell line J774A.1, porcine uterine luminal epithelial cells and human lung CD4+ T cells.

Product Properties

ALogP5.1

Associated Targets

CCR5 Tclin C-C chemokine receptor type 5 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
INCHI InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
InChi Key GSNHKUDZZFZSJB-HLMSNRGBSA-N
Canonical SMILES CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
Isomeric SMILES CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
WGK Germany 1
Alternate CAS 2414315-81-2,376348-65-1
PubChem CID 3002977
MeSH Entry Terms 4,4-difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide;maraviroc;Selzentry;UK 427,857;UK 427857;UK-427,857;UK-427857;UK427,857;UK427857
Molecular Weight 513.67

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

7 results found

Lot NumberCertificate TypeDateItem
I2219220Certificate of AnalysisJul 12, 2024 M125486
I2219221Certificate of AnalysisJul 12, 2024 M125486
K2301452Certificate of AnalysisOct 25, 2023 M125486
K2301453Certificate of AnalysisOct 25, 2023 M125486
K2301454Certificate of AnalysisOct 25, 2023 M125486
J2127239Certificate of AnalysisAug 01, 2023 M125486
I2219222Certificate of AnalysisJul 21, 2022 M125486

Chemical and Physical Properties

SolubilityDMSO: >30 mg/ml

Safety and Hazards(GHS)

Pictogram(s) GHS08
Signal Warning
Hazard Statements

H373:Causes damage to organs through prolonged or repeated exposure

H412:Harmful to aquatic life with long lasting effects

Precautionary Statements

P273:Avoid release to the environment.

P501:Dispose of contents/container to ...

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P319:Get medical help if you feel unwell.

WGK Germany 1

Related Documents

References

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C et al..  (2005)  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity..  Antimicrob Agents Chemother,  49  (11): (4721-32).  [PMID:16251317]
2. Mencarelli A, Cipriani S, Francisci D, Santucci L, Baldelli F, Distrutti E, Fiorucci S.  (2016)  Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis..  Sci Rep,  (3): (30802).  [PMID:27492684]
3. Takeuchi T, Kameda H.  (2012)  What is the future of CCR5 antagonists in rheumatoid arthritis?.  Arthritis Res Ther,  14  (2): (114).  [PMID:22494450]
4. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP et al..  (2014)  International union of basic and clinical pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands..  Pharmacol Rev,  66  (4): (918-47).  [PMID:25026896]

Solution Calculators